Humanigen, Inc. (NASDAQ: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor. Humanigen is developing lenzilumab as a treatment for chronic myelomonocytic leukemia and acute graft versus host disease. Humanigen is also exploring use of lenzilumab to prevent toxicities associated with CAR-T therapy through investigator-initiated trials. Humanigen is also developing an antibody drug conjugate (ADC) utilizing its EphA-3 targeted monoclonal antibody ifabotuzumab (ifab) for solid tumors. For more information, visit www.humanigen.com and follow Humanigen on Twitter.
Company profile
Ticker
HGENQ, HGEN
Exchange
Website
CEO
Cameron Durrant
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KALOBIOS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Humanigen, Ltd. • Humanigen Australia • Humanigen Europe, Ltd. ...
IRS number
770557236
HGENQ stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
8 Jan 24
25-NSE
Exchange delisting
12 Oct 23
8-K
Departure of Directors or Certain Officers
14 Sep 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
25 Apr 23
8-K
Other Events
19 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
Latest ownership filings
4
Dale Chappell
20 Oct 23
SC 13G/A
Murchinson Ltd.
1 Feb 23
SC 13G/A
Valiant Capital Management, L.P.
10 Aug 22
4
Cheryl Buxton
29 Jul 22
4
John Hohneker
29 Jul 22
4
RONALD BARLIANT
29 Jul 22
4
Adrian Kilcoyne
29 Jul 22
4
Dale Chappell
29 Jul 22
4
Rainer J. Boehm
29 Jul 22
4
Edward P. Jordan
29 Jul 22
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.10 mm | 3.10 mm | 3.10 mm | 3.10 mm | 3.10 mm | 3.10 mm |
Cash burn (monthly) | 2.35 mm | 5.49 mm | 1.41 mm | 4.33 mm | 2.35 mm | 5.36 mm |
Cash used (since last report) | 29.75 mm | 69.37 mm | 17.85 mm | 54.79 mm | 29.75 mm | 67.76 mm |
Cash remaining | -26.65 mm | -66.28 mm | -14.75 mm | -51.70 mm | -26.65 mm | -64.66 mm |
Runway (months of cash) | -11.3 | -12.1 | -10.4 | -11.9 | -11.3 | -12.1 |
Institutional ownership, Q2 2023
13.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 7 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 849.26 mm |
Total shares | 15.50 mm |
Total puts | 0.00 |
Total calls | 31.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Cheval | 10.09 mm | $29.86 mm |
Vanguard | 1.71 mm | $260.60 mm |
BK Bank Of New York Mellon | 878.33 k | $133.86 mm |
Geode Capital Management | 861.96 k | $131.36 mm |
BLK Blackrock | 812.40 k | $123.81 mm |
STT State Street | 188.68 k | $28.75 mm |
Two Sigma Investments | 153.89 k | $23.45 mm |
Two Sigma Securities | 152.14 k | $23.19 mm |
NTRS Northern Trust | 140.54 k | $21.42 mm |
MS Morgan Stanley | 62.00 k | $9.45 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Oct 23 | Chappell Dale | Common Stock, $0.001 par value | Sell | Dispose S | Yes | No | 0.011 | 276,210 | 3.04 k | 8,398,871 |
18 Oct 23 | Chappell Dale | Common Stock, $0.001 par value | Sell | Dispose S | Yes | No | 0.011 | 75,887 | 834.76 | 2,307,530 |
18 Oct 23 | Chappell Dale | Common Stock, $0.001 par value | Sell | Dispose S | Yes | No | 0.011 | 34,253 | 376.78 | 1,041,536 |